# Beximco Pharmaceuticals Limited (BXP.L) fundamentals

Data as of 2026-11-04. LSE, United Kingdom. Sector: Healthcare / Pharmaceuticals. Price 54p, market value 241 millionp.

## Valuation
- **P/E (trailing): 4.5×**. Beximco Pharmaceuticals Limited trades at 4.5× trailing earnings. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 0.1×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.00**. A PEG of 0.00 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 0.0×**. Each dollar of revenue is priced at 0.0×, a low multiple typical of thin-margin businesses or out-of-favour stocks.
- **Price / book: 0.0×**. The shares trade below book value, which can signal a bargain or a balance sheet the market doubts.
- **EV / EBITDA: 0.2×**. Enterprise value is 0.2× operating earnings before depreciation, the multiple that ignores how the company is financed; below 8× is inexpensive for most sectors.
- **Free-cash-flow yield: 1740.7%**. Free cash flow equals 1740.7% of the market value. Above 5% is generally attractive.
- **Earnings yield: 22.2%**. The inverse of the P/E: 22.2% of the price is earned each year.

## Profitability
- **Gross margin: 47.9%**. Beximco Pharmaceuticals Limited keeps 47.9% of revenue after the direct cost of what it sells.
- **Operating margin: 21.3%**. 21.3% of revenue is left after running the business, a healthy level in most sectors.
- **Net margin: 14.1%**. 14.1% of each dollar of sales reaches the bottom line.
- **Return on equity: 13.1%**. 13.1% on shareholders' equity is solid.
- **Return on invested capital: 16.1%**. Return on all capital, debt included, is 16.1%: comfortably above what that capital costs.
- **Return on assets: 11.8%**. Each dollar of assets produces 11.8% of profit.

## Growth
- **Revenue growth (1 yr): 10.7%** (3-yr 12.3%/yr). Revenue grew 10.7% over the last year.
- **EPS growth (1 yr): 19.1%** (3-yr 10.7%/yr). Earnings per share rose 19.1%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): 22.6%/yr**. Free cash flow has compounded at 22.6% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 0.09**. Debt is 0.09 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 0.2×**. It would take 0.2 years of operating earnings to repay net borrowings, within the comfortable range.
- **Interest coverage: 16.9×**. Operating profit covers interest 16.9× over, a safe margin.
- **Current ratio: 2.83** (quick 1.12). Current assets cover the next year's liabilities 2.83 times.
- **Altman Z-score: 2.38**. A Z-score of 2.38 is in the grey zone; not distressed, not clearly safe.
- **Piotroski F-score: 9/9**. 9 of 9 fundamental checks pass: strong and improving financials.

## Dividends
- **Dividend yield: 5.30%** (0p per share, trailing). Beximco Pharmaceuticals Limited yields 5.30%, an income-level yield.
- **Payout ratio: 23%** (38% of free cash flow). 23% of earnings goes out as dividends, leaving room to keep raising it.

## Price and momentum
- **Total return (1 yr): 25.7%** (YTD 27.2%, 3-mo 4.9%). The shares are up 25.7% over twelve months including dividends.
- **From 52-week high: -16.9%** (12605.9% above the low). Trading 17% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 50**. An RSI of 50 is neutral.
- **Beta (1 yr): 5.58**. Beta of 5.58 against the FTSE All-Share: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=BXP.L · Page: https://foliofundamentals.com/stocks/bxp.l

Not investment advice.